KDA Group
KDA Group is a Canadian healthcare technology company developing AI-powered SaaS platforms (Adherize+, Medherize, KRx) for therapeutic adherence, oncology monitoring, and electronic prescribing, serving community pharmacies, hospital oncology centers, and medical practices across Quebec, Canada, and expanding into the U.S. and Asia.
- Company typePublic
- Founded2009
- HeadquartersThetford Mines, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What KDA Group does
KDA Group Inc. (TSXV: KDA) is a publicly-traded Canadian healthcare technology company founded in 2009 and headquartered in Thetford Mines, Quebec, that develops AI-powered digital health platforms for the pharmaceutical ecosystem. The company operates a platform-plus-modules architecture centered on three core products: Adherize+, a therapeutic adherence SaaS platform that proactively contacts patients via SMS/email for follow-up and claims up to 35% revenue recovery for pharmacies without human intervention; Medherize, a specialized therapeutic monitoring platform initially focused on metastatic breast cancer patients on CDK 4/6 inhibitors, integrating with Quebec's Dossier Santé Québec (DSQ) provincial health record for lab results and interprofessional coordination; and KRx, a predictive electronic prescription software with Vigilance Santé drug database integration, adapted for domestic and international regulatory frameworks. The company also retains Covapharm (SaaS drug treatment optimization acquired 2022) and acquired worldwide rights (excluding US/Europe/UK/Canada) to the ZRx Digital Prescriber from ZoomMed in 2023. The technology is integrated with provincial health records (DSQ certification received 2025), pharmacy management systems, and clinical workflows spanning oncologists, pharmacists, and patients on a single digital platform.
KDA operates a B2B SaaS business model with enterprise field sales targeting community pharmacies (Horizon Santé, Jean Coutu banners), hospital oncology centers (CHU de Québec – Hôpital du Saint-Sacrement), and physicians/dental clinics. Revenue streams derive from recurring platform subscriptions and licensing for Adherize+, Medherize, and Covapharm, with KRx offered as comprehensive e-prescription software. Pricing is not publicly disclosed and follows a quote-based B2B engagement model. Customer segments are vertically segmented into Community Pharmacies, Oncology/Hospital Centers, Physicians/Medical Practices, and Specialized Healthcare Institutions. The company deploys through direct enterprise sales to healthcare institutions, channel partnerships (Cavendish Investment Corp. for Asian markets including Hong Kong), and U.S. direct sales following the November 2025 establishment of a U.S. subsidiary for Medherize's 2026 commercial launch. The company is led by Jean-Marc Léveillé (President and interim CEO as of February 2026) and employs 11–50 staff, with operations primarily in Quebec, Canada and an expanding footprint into the United States and Asia.
KDA Group firmographics
Firmographics- Name
- KDA Group
- Legal name
- Groupe KDA inc.
- Website
- https://groupkda.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- KDA Group is a Canadian healthcare technology company developing AI-powered SaaS platforms (Adherize+, Medherize, KRx) for therapeutic adherence, oncology monitoring, and electronic prescribing, serving community pharmacies, hospital oncology centers, and medical practices across Quebec, Canada, and expanding into the U.S. and Asia.
- Ownership category
- akta.pro rank
KDA Group industry classification
Industry- Product category
- Healthcare Software (Therapeutic Adherence & Electronic Prescribing)
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Virtual Pharmacy & Medication Management Integration Platforms (HLALABAL)
- akta.pro secondary industries
- Medication Pricing, Copay Assistance & Patient Financial Support Tools (HLACAKAN), Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)
Keywords
Where KDA Group is headquartered
LocationHeadquarters
- HQ city
- Thetford Mines
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
KDA Group business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Adherize+ SaaS Subscriptions: Adherize+ is offered as a platform solution to pharmacies, generating recurring revenue through subscription or per-transaction fees based on adherence management and revenue recovery services. The platform's automated adherence management can generate up to 35% revenue recovery for pharmacies, suggesting a performance or transaction-based component.
- Medherize Platform Licensing: Medherize is deployed across hospital centers and community pharmacies for specialized medication monitoring. Revenue likely derives from platform licensing to healthcare institutions, with deployments at Hôpital du Saint-Sacrement (CHU de Québec) and community pharmacy banners.
- KRx Electronic Prescriber: KRx e-prescriber is offered as a comprehensive electronic prescription software for general and specialized medical environments, adapted to regulatory frameworks across markets. Revenue model for this product is not publicly disclosed but likely involves licensing or subscription.
- Covapharm SaaS: Covapharm is a software-as-a-service platform for pharmacological treatment optimization and drug monitoring, generating recurring SaaS revenue.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels7 records
KDA Group product offering
Product offeringCore offering
KDA Group develops and licenses proprietary digital health software platforms — Adherize+, Medherize, KRx, Covapharm, and ZRx — that enable community pharmacies, hospital oncology teams, and medical practices to manage therapeutic adherence, electronic prescribing, and patient cycle monitoring. Offerings are delivered primarily as SaaS subscriptions and software licenses, with regulatory (DSQ) certification enabling integration with Quebec's provincial health infrastructure and the RAMQ prescription drug plan.
Product overview
KDA Group operates a platform-plus-modules architecture centered on healthcare technology solutions. The core Adherize+ platform provides therapeutic adherence management through interactive patient communication and automated follow-up, while Medherize serves as a specialized oncology extension focused on metastatic breast cancer patients using CDK 4/6 inhibitors. KRx provides the electronic prescribing capability (including dental-specific KRx Dental), and Covapharm offers standalone drug optimization SaaS. These products share infrastructure (DSQ integration, pharmacy connectivity) and can operate independently or as an integrated care continuum connecting oncologists, pharmacists, and patients.
Differentiator
Problem solved
Functional benefit
Brands
- Adherize+: Interactive healthcare application for therapeutic adherence and patient follow-up, connecting healthcare professionals and patients through real-time monitoring and personalized communication.
- Medherize
- Covapharm
- KRx
Products and services
- Adherize+
Quantifiable outcome
- Up to 35% revenue recovery for pharmacies through automated adherence management without human intervention
- +8 more outcomes
Companies that use KDA Group
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
KDA Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability6 records
Feature5 records
KDA Group partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- AstraZeneca CanadacoreKDA Group announced collaboration with AstraZeneca Canada to integrate clinical alerts into its Medherize platform to support next-generation sequencing (NGS) testing for breast cancer patients in Québec. The project aims to improve genomic testing access, clinical decision-making, and personalized care, with plans for expansion beyond Hôpital du Saint-Sacrement. AstraZeneca is a major global pharmaceutical company bringing clinical expertise and potentially patient referral pathways to the platform.
- CHU de Québec – Université LavalcoreKDA Group signed a partnership and collaboration agreement with CHU de Québec for the deployment of Medherize at Hôpital du Saint-Sacrement, one of CHU's five hospital facilities. The partnership focuses on improving treatment management for complex medical conditions. The platform is expected to expand across Quebec, Canada, and internationally. The partnership has garnered interest from several pharmaceutical companies. Nearly 200 patients were being monitored as of December 2025. An independent evaluation by the Breast Disease Centre confirmed clinical and organizational benefits among 243 patients.
- Pharmacie Horizon SantécoreGroupe Technologique KDA (Tech KDA) signed a letter of intent with Pharmacie Horizon Santé and Dr. Éric Poirier to integrate the Medherize platform, addressing complex challenges in managing outpatient oncology treatments for breast cancer patients. Horizon Santé represents a pharmacy banner for community pharmacy deployment of Medherize.
- Dr. Éric PoiriercoreDr. Éric Poirier, surgical oncologist at the Clinique des Maladies du Sein at CHU de Québec – Université Laval, collaborated with KDA in developing the Medherize platform. His clinical expertise in breast oncology guided platform features including CDK 4/6 inhibitor monitoring and adverse event management. Dr. Poirier continues as a key clinical advisor and partner.
- Cavendish Investment Corp.minorKDA engaged Cavendish Investment Corp. to market Groupe Technologique KDA's technology products throughout the Asian market, including Hong Kong. This channel partnership supports KDA's international expansion into Asia.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
KDA Group competitors and assessment
Company assessmentDirect peers
- Medisafe: Medication adherence platform offering patient-facing reminders, adherence tracking, and population-level analytics for pharma and providers. Directly comparable to Adherize+ in therapeutic adherence, though Medisafe operates at a global scale rather than a Quebec-anchored model.
- DrFirst: Provider of electronic prescribing, medication management, and clinical decision support software widely deployed across U.S. health systems. Most directly comparable to KDA's KRx e-prescriber and Covapharm offerings in functional scope and target buyer.
- Tabula Rasa HealthCare: Medication risk mitigation and pharmacovigilance platform providing medication optimization, adherence, and outcomes analytics to pharmacies and at-risk provider groups. Closely comparable to Covapharm's drug optimization and Adherize+ adherence functionality.
- DoseSpot: e-Prescribing and medication management software integrated into EHR and practice management systems, with significant presence in dental and specialty clinics. Comparable to KRx and KRx Dental in product scope and customer base.
- emocha Health: Directly Observed Therapy and digital medication adherence platform focused on complex conditions including hepatitis C, tuberculosis, and opioid use disorder. Comparable to Medherize in using mobile monitoring to confirm adherence for serious disease therapies.
- WellDoc: Digital therapeutics platform for chronic disease (diabetes, hypertension) combining connected devices, AI-driven coaching, and EHR integration. Comparable to Medherize's chronic-condition monitoring approach and to Adherize+ in adherence management.
- Voluntis: Digital therapeutics platform for chronic and oncology conditions with companion apps, patient monitoring, and pharma partnerships. Comparable to Medherize in oncology-focused digital monitoring and pharma-sponsored care models.
- RxAnte: Medication adherence analytics platform using predictive modeling to identify at-risk patients for health plans and PBMs. Comparable to Adherize+'s adherence analytics and revenue-recovery value proposition, though serving payers rather than community pharmacies.
Broad incumbents
- Surescripts: Dominant U.S. health information network for electronic prescribing and clinical interoperability, connecting virtually all U.S. pharmacies and prescribers. Represents the entrenched incumbent that KRx must compete against or partner with for any U.S. e-prescribing ambitions.
Emerging players
- Pillsy: Smart pill bottle and medication adherence platform combining connected hardware with patient engagement software. Adjacent competitor in the broader patient adherence technology category relevant to Adherize+.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
KDA Group social profiles
Digital presenceKDA Group compliance and trust
Trust signalCompliance2 records
KDA Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
KDA Group leadership team
Management profileNumber of profiles
Profiles9 records
KDA Group subsidiaries and ownership
Company hierarchySubsidiaries4 records
KDA Group funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KDA Group M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KDA Group
What does KDA Group do?
KDA Group develops and licenses proprietary digital health software platforms — Adherize+, Medherize, KRx, Covapharm, and ZRx — that enable community pharmacies, hospital oncology teams, and medical practices to manage therapeutic adherence, electronic prescribing, and patient cycle monitoring. Offerings are delivered primarily as SaaS subscriptions and software licenses, with regulatory (DSQ) certification enabling integration with Quebec's provincial health infrastructure and the RAMQ prescription drug plan.
Is KDA Group a public or private company?
KDA Group is a public company. It is classified as public and is currently operating.
When was KDA Group founded?
KDA Group was founded in 2009. It employs 11 to 50 people.
Where is KDA Group based?
KDA Group is headquartered in Thetford Mines, Canada, in the North America region.
How does KDA Group make money?
Four revenue lines are on record. Adherize+ SaaS Subscriptions are the primary driver. The others are medherize Platform Licensing, KRx Electronic Prescriber and covapharm SaaS.
Who are KDA Group's main competitors?
Direct peers on record are Medisafe, DrFirst, Tabula Rasa HealthCare, DoseSpot, emocha Health, WellDoc, Voluntis and RxAnte. Surescripts is listed as a broad incumbent. Pillsy is listed as an emerging player.
Does KDA Group have an API?
No public API is recorded for KDA Group.
What industry is KDA Group in?
KDA Group's product category is Healthcare Software (Therapeutic Adherence & Electronic Prescribing). Its primary akta.pro industry code is HLALABAL, Virtual Pharmacy & Medication Management Integration Platforms, with a secondary code of HLACAKAN, Medication Pricing, Copay Assistance & Patient Financial Support Tools. Its NAICS code is 5132 and its SIC code is 7372.